综合老年学评估预测老年非霍奇金淋巴瘤患者的毒性事件,并进行前期治疗的嵌入式试验研究
This study will evaluate the ability of a largely self-administered geriatric assessment (GA) to predict toxicity in non-Hodgkin Lymphoma (NHL) patients ≥60 years old receiving chemotherapy or chemoimmunotherapy.
研究概览
研究类型
注册 (实际的)
阶段
- 不适用
联系人和位置
学习地点
-
-
New Jersey
-
Basking Ridge、New Jersey、美国、07920
- Memorial Sloan Kettering Basking Ridge
-
Middletown、New Jersey、美国、07748
- Memorial Sloan Kettering Monmouth
-
Montvale、New Jersey、美国、07645
- Memorial Sloan Kettering Bergen
-
-
New York
-
Commack、New York、美国、11725
- Memorial Sloan Kettering Commack
-
Harrison、New York、美国、10604
- Memorial Sloan Kettering Westchester
-
New York、New York、美国、10065
- Memorial Sloan Kettering Cancer Center
-
Rockville Centre、New York、美国、11570
- Memorial Sloan Kettering Rockville Centre
-
Uniondale、New York、美国、11553
- Memorial Sloan Kettering Nassau
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
Subjects meeting the following criteria will be eligible for enrollment in the study (unless excluded):
- ≥60 years old
- Pathologically confirmed NHL.
- Must meet criteria for initiation of treatment; consisting of:
- Aggressive histology, or
- Indolent histology with one of the following markers of large tumor burden (67):
- Any nodal or extranodal tumor mass ≥7cm in greatest dimension
- ≥3 nodal masses that are each ≥3 cm in greatest dimension
- Systemic symptoms
- Cytopenias (leukocytes <1 × 109/L and/or platelets ,100 × 109/L)
- Substantial splenomegaly
- Serous effusion (plural effusion or peritoneal ascites)
- Orbital or epidural involvement
- Ureteral compression
- Leukemic phase (malignant cells ≥5 x 109/L)
- Must be starting a new chemotherapy regimen (patients whose treatment regimen includes an immunomodulatory agent such as lenalidomide or small molecule targeted agents such as Ibrutinib or Idelelasib will be included in the study; patients being treated with a single agent monoclonal antibody will not be included).
- Fluent in English (because not all components of the GA have been validated in other languages)
- Able to provide informed consent
In addition to the above, subjects meeting the following criteria will be enrolled in the pre-phase arm of the study, until the accrual target for that arm is reached:
- Age ≥ 70 years OR KPS ≤ 70
- Pathologically confirmed diagnosis of DLBCL, with or without simultaneous or antecedent indolent lymphoma.
- Previously untreated for DLBCL
- Intended initial treatment to include ≥2 cycles of R-CHOP, R-EPOCH or R-CEPP using standard doses and schedule.(68, 69) R-CHOP chemoimmunotherapy may be given every 14 days or every 21 days. (4, 70)
Exclusion Criteria:
Subjects meeting the following criteria will be excluded from enrollment in the study:
- Enrollment in a Phase I trial
- Previously enrollment in this study
- Patients scoring ≥ 11 on the BOMC (implying cognitive impairment) will be excluded since their ability to reliably complete the questionnaire will be in doubt Subjects meeting the following criteria will be excluded from enrollment in the pre-phase arm of the study, but may be included in the GA only arm.
- Contraindication to use of rituximab or prednisone including:
- Uncontrolled diabetes mellitus
- Systemic fungal infection
- Evidence of active hepatitis B infection (i.e. patients testing positive hepatitis B surface antigen or viral DNA by PCR analysis) will be excluded. Patients with evidence of past infection without active viremia (i.e. positive hepatitis B core antibody, negative hepatitis B surface antigen and negative hepatitis B DNA PCR) will be treated with entecavir as per institutional guidelines and may be included in the study.
- History of any serious adverse reaction to either a corticosteroid or rituximab not including rituximab infusion reactions ≤ Grade 3.
- Patients enrolled on another clinical trial which prohibits the use of pre-phase therapy or any of its components.
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:非随机化
- 介入模型:并行分配
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:Pre-Phase Arm
They will be treated with a single dose of rituximab 375mg/m2, once, by intravenous infusion 3-10 days prior to initiation of planned R-CHOP-like chemoimmunotherapy, and prednisone 50mg to 100 mg (preferred dose is 100mg) PO daily for 5-7 days (preferred duration is 7 days) of the 14 days prior to initiation of planned R-CHOP, R-EPOCH or R-CEPP chemoimmunotherapy. Pre-phase therapy may be given in either the inpatient or outpatient setting. After completion of a single course of pre-phase rituximab and prednisone as described above, further treatment will be according to the choice of the attending physician, in accordance with appropriate medical practice. It is expected, based on the inclusion criteria, that patients enrolled on the pre-phase arm will most often receive initial therapy consisting of R-CHOP, R-EPOCH or RCEPP chemoimmunotherapy for ≥ 2 cycles, but alternative therapies as deemed appropriate by the treating physician will not be considered violations of this protocol. |
|
|
实验性的:Geriatric Assessment (GA) only arm
Patients enrolled on the GA only arm of the study will be treated according to the choice of the attending physician. This arm of the study is non-therapeutic. |
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Toxicity Assessment
大体时间:3 years
|
Hospitalization during or within 30 days following chemotherapy Dose delay or reduction to a dose intensity ≤80% of the planned dose intensity. Dose reductions occurring prior to cycle 1 of chemotherapy will be counted as events. Discontinuation of chemotherapy due to toxicity Grade 3 or higher non-hematologic toxicity Grade 4 or higher hematologic toxicity. Using the NCI CTCAE v4.0 toxicity grading |
3 years
|
合作者和调查者
调查人员
- 首席研究员:Paul Hamlin, MD、Memorial Sloan Kettering Cancer Center
出版物和有用的链接
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (估计的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他相关的 MeSH 术语
其他研究编号
- 13-028
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.